2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3696 Real-world impact of line of therapy on outcomes with CD20xCD3 bispecific antibodies (BsAb) in relapsed or refractory large B-cell lymphoma (R/R LBCL): Results from a multicenter cohort study

Saad Nasir, MD, Narendranath Epperla, MD, MS, FACP2, Ruitao Lin, PhD3, Andrew P. Jallouk, MD, PhD4, Lorenzo Falchi, MD5, Ayushi Chauhan, MD6, Geoffrey Shouse, DO PhD7, Swetha Kambhampati Thiruvengadam8, Yazeed Sawalha, MD9, Ajay Major, MD, MBA10, Reid W Merryman, MD11, Steven Bair, MD12, Jennifer L. Crombie, MD13, Amy A. Ayers14, Mehdi Hamadani, MD15, Allison Marie Bock, MD16, Shakthi P. Bhaskar, MD17, Omnia Farahat, MD18, Alexey V. Danilov, MD, PhD19, Matthew A. Lunning, DO, FACP20, Sonia Godbole21, Alex Francisco Herrera, MD22, Christopher R. Flowers Jr, MD, MS23, Gilles Salles I, MD, PhD24, Gulrayz Ahmed, MD25, Sairah Ahmed, MD26
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Vanderbilt University Medical Center, Nashville, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
10 University of Colorado School of Medicine, Aurora, Colorado, United States
11 Dana Farber Cancer Institute, Boston, United States
12 University of Colorado School of Medicine, Aurora, Colorado, United States
13 Dana Farber Cancer Institute, Boston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
16 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
17 Vanderbilt University Medical Center, Nashville, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 City of Hope, Duarte, California, United States
20 University of Nebraska Medical Center, Omaha, Nebraska, United States
21 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
22 City of Hope, Duarte, California, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 Memorial Sloan Kettering Cancer Center, New York, United States
25 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: BsAbs have demonstrated substantial clinical benefit in patients (pts) with R/R LBCL and are increasingly adopted in routine clinical practice. However, pivotal trials predominantly enrolled pts in the third-line or later (≥3L) setting. With the expanding real-world use of BsAbs across earlier and later lines of therapy (LOT), the impact of LOT on clinical outcomes remains unclear.

Method: This is a multicenter retrospective study of consecutive patients with R/R LBCL treated with commercial CD3xCD20 BsAbs across 10 US centers within the Collaborative US Bispecific Consortium (CUBIC).  Patients were stratified by line of therapy (LOT) and treatment approach. Treatment approach was divided into combination therapy (CT) and monotherapy (MT). Within each approach we compared outcomes across three LOT groups (2L, 3L, and ≥4L). Efficacy outcomes included overall response rate (ORR), complete response (CR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). PFS and OS were estimated using the Kaplan-Meier method, with 12-month (mo) survival rates. Multivariable Cox regression models adjusted for age, bulky disease, double/triple-hit lymphoma (DHL), ECOG, elevated LDH, primary refractory disease (PRD), prior ASCT, and prior CAR-T were used to evaluate the association between LOT and outcomes, comparing 2L versus ≥3L for CT and 3L versus ≥4L for MT.

Results: Of 471 pts included, 266 received glofitamab (glofit) and 205 epcoritamab (epcor). BsAbs were administered as CT (n=184; 2L n=53, 3L n=59, ≥4L n=72; glofit n=121, epcor n=40) or MT (n=287; 2L n=14, 3L n=86, ≥4L n=187; glofit n=145, epcor n=165. Glofit and epcor were commonly used with Gem-Ox as CT (n=59, 48% and n=14, 35%, respectively). The median age was 70 yrs (IQR, 61–78), 66% (n=326) of pts were male, and 74% (n=365) were White. The median number of prior LOT was 3 (IQR, 2–4), and 48% had received prior CAR-T.

Among pts receiving CT, median follow-up was 9.3 mo. Earlier-line treatment was associated with better CR rate (43% vs 40% vs 23%, p=0.039), and an improved PFS, with a median PFS of 5.6, 6.0, and 2.8 mo in the 2L, 3L, and ≥4L, respectively (p=0.005). The ORR were similar across LOT (60% vs 64% vs 45%, p=0.077). Correspondingly, 12-mo PFS rates were highest in the 2L CT cohort (49% vs 39% vs 21%). Median OS at 12-mo was 55%, 53%, 42% in the 2L, 3L, and ≥4L, respectively. The overall median DOR was 6.7 mo and did not differ significantly by LOT (2L, NR; 3L, 5.7 mo; ≥4L, 5.1 mo; p=0.455).

Among pts receiving MT, median follow-up was 17.7 mo. ORR, CR rate, median PFS, and median OS were comparable across LOT. The ORR for MT cohort was 49%, including 50% in 2L, 48% in 3L, and 49% in the ≥4L (p=0.990). Median PFS was 3.6 mo overall and 2.9, 2.6, and 3.7 mo in the 2L, 3L, and ≥4L cohorts, respectively (p=0.854). Median OS was 9.3 mo overall and 9.2, 7.5, and 10.8 mo in the 2L, 3L, and ≥4L cohorts, respectively (p=0.546). The 12-month PFS rates were highest in 3L (19 vs 34% vs 31%), while the corresponding OS rates were 31%, 39%, and 44% in the 2L, 3L, and ≥4L. For MT the overall median DOR was 17.4 mo and did not differ significantly by LOT (2L, 7.3 mo; 3L, 13.9 mo; ≥4L, 17.7 mo; p=0.405).

On multivariable analysis, LOT was not independently associated with PFS or OS, either among pts receiving CT (2L vs ≥3: PFS, HR 1.74, 95% CI 0.94–3.24, p=0.079; OS, HR 1.83, 95% CI 0.83–4.05, p=0.133) or among those receiving MT (3L vs ≥4L: PFS, HR 0.97, 95% CI 0.67–1.40, p=0.875; OS, HR 0.86, 95% CI 0.59–1.27, p=0.458). Among pts receiving CT, DHL and PRD were independently associated with inferior PFS. Factors associated with inferior OS included advancing age, DHL, ECOG ≥2, elevated LDH, PRD. Among pts receiving MTs, ECOG ≥2, elevated LDH, and PRD were associated with inferior PFS and OS.

Conclusion: Earlier-line use of BsAb CT in R/R LBCL was associated with a higher CR and improved PFS, although LOT was not independently associated with OS benefit. In contrast, outcomes with MT were similar across LOT. Baseline disease biology, DHL, PRD, elevated LDH, and ECOG ≥2, were strong determinants of outcomes. These findings support earlier use of BsAb-based strategies and highlight the importance of patient and disease risk factors in outcome prediction and warrant validation in future studies. However, retrospective design and non-randomized treatment selection may confound comparisons between CT and MT groups.

Saad Nasir, MD: No relevant conflicts of interest to declare.